8800 Health Science Center Parkway
Bryan, TX 77807-1107
United States
302 355 0650
https://www.ibioinc.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 26
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Martin B. Brenner D.V.M., Ph.D. | CEO & Chief Scientific Officer | 577.31k | N/A | 1971 |
Mr. Felipe Duran | Chief Financial Officer | 1.07M | N/A | 1980 |
Stephen Kilmer | Investor Relations Officer | N/A | N/A | N/A |
Mr. Marc Banjak J.D. | General Counsel | N/A | N/A | N/A |
Mr. Robert B. Kay | Interim Secretary & Interim Treasurer | 92.69k | N/A | 1940 |
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
iBio, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 4; Compensation: 10.